- Abecma Delivers Sustained PFS vs Standard Regimens in Earlier Lines of Therapy for R/R Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
- Actinium’s Four Presentations Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study
- Amgen highlights hematology portfolio
- Analyses Of Kite’s Yescarta®CAR T-Cell Therapy Support Curative Potential In Patients With Non-Hodgkin Lymphomas
- Aptose Tuspetinib Clinical Data Featured in Oral Presentation
- Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in RRMM Patients
- Autolus Therapeutics Presents Clinical Data Updates
- BMS Announces Data from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
- BMS Presents New Data Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a 2L Treatment in High-Risk Follicular Lymphoma and in R/R CLL
- CARsgen Presents Updated Research Results on Zevor-cel
- Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
- Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from Phase 1/1b T Cell Lymphoma Trial
- Curis Presented Clinical Data from the TakeAim Leukemia Study
- DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma
- GlycoMimetics Announces Independent Presentations on Uproleselan including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
- Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma
- IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients
- ImmunoGen Presents Findings from Newly Diagnosed AML Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax
- Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
- Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant
- Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
- Long-Term Data For Kite’s Yescarta® CAR T-Cell Therapy Demonstrate High Rate Of Durable Response In Patients With High-Risk Large B-Cell Lymphoma
- MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
- Nkarta Presents NKX101 Clinical Data
- New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
- New Analyses Support The Potential Long-Term Response And Safety Of Kite’s Tecartus® In Patients With Aggressive Blood Cancers
- New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
- New data for Roche’s Columvi and Lunsumio support continued benefit for people with lymphoma
- New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
- Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127
- Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma
- Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in 1L HR-MDS and TP53 mutant (TP53m) AML Patients
- Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
- Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma
- TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101
- Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented
- Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented
Menu
